Predict your next investment

HEALTHCARE | Pharmaceuticals / Drugs
elevationpharma.com

See what CB Insights has to offer

Executives

4

Board of Directors

4

Elevation Pharmaceuticals Board of Directors

4 Board of directors

Elevation Pharmaceuticals has 4 board of directors, including Brenton Ahrens.

Name

Firm

Work History

Other Seats

Brenton Ahrens

Brent is General Partner (West Coast) at Canaan Partners. Brent joined Canaan in 1999 and throughout his tenure has lead investments in an array of healthcare companies, with a focus on biopharma and medtech. Brent's current investment and Board seats include device developer and manufacturer Abyrx, reflux device company EndoGastric Solutions, immune-oncology drug developer Grey Wolf Therapeutics, antibiotic developer Iterum Therapeutics, device maker for chronic back pain Relievant MedSystems, life sciences tool company Unchained Labs and pain management developer Semnur. Some of his previous companies include Dexcom (DXCM), Revivant (acquired by Zolle), Peninsula Pharmaceuticals (acquired by J&J), Cerexa (acquired by FRX and Spinifex Pharmaceuticals (acquired by NVS). Prior to joining Canaan, Brent worked in both commercial and technical roles at General Surgical Innovations, Ethicon Endo-Surgery (J&J) and IAP Research. Brent earned an M.B.A. from the Tuck School of Business at Dartmouth College after graduating with a B.S. and M.S. in mechanical engineering from the University of Dayton.

Elevation Pharmaceuticals

Heath Lukatch

Heath is Founder and Managing Partner at Red Tree Venture Capital. He has extensive experience building and advising biotech and pharma companies.

Elevation Pharmaceuticals

Heather Preston

Heather Preston MD joined Pivotal in 2018 and brings 30 years of healthcare experience. Most recently she was a Firm Partner and Managing Director at TPG Biotech and she is currently a Senior Advisor to TPG. Prior to joining TPG in 2005, Dr. Preston spent two years investing with JP Morgan Partners and she was also an Entrepreneur-in-Residence with New Enterprise Associates. Prior to becoming a venture capital investor, Heather spent five years at McKinsey & Co. in New York, where she was a leader of their pharmaceutical and medical products consulting practice. She advised large pharmaceutical companies and biotechnology companies on critical strategic issues such as R&D portfolio prioritization, M&A opportunities, new technology acquisitions, new product launches and product growth strategies. Heather currently serves on the board of directors of Oxford Biomedica (LSE:OXB); Karuna Therapeutics (NASDAQ:KRTX); Entasis Therapeutics (NASDAQ:ETTX), Unchained Labs, Azura Opthalmics, Fusion Pharmaceuticals, Akouous and Avalyn Pharmaceuticals. She has previously served on multiple private and public boards including Albireo (NASDAQ:ALBO), Alder BioPharmaceuticals (NASDAQ:ALDR) (Acquired by Lundbeck in 2019), Aptalis Pharma (acquired by Forest Labs in 2014), and Elevation Pharmaceuticals (acquired by Sunovion in 2012). She was responsible for TPG Biotech’s investment in Par Pharmaceuticals (acquired by Endo Pharmaceuticals in 2015). Heather has an undergraduate degree in biochemistry from the University of London and a medical degree from the University of Oxford. She completed a post-doctoral fellowship in molecular biology at the Dana Farber Cancer Institute, Harvard University and trained in Internal Medicine at the Massachusetts General Hospital, Harvard and sub-specialized in Gastroenterology and Hepatology at UCSF. During her academic medical career, she was the recipient of a Fulbright Scholarship, a Fulbright Cancer Research Scholarship, a Harlech Scholarship and a Science and Engineering Research Council Post-doctoral Fellowship Award. Dr. Preston also serves on the Board of Trustees for the Harvard Discovery Council, the Fine Arts Museums of San Francisco, Saint Luke’s School and the Harlech Scholarship Foundation.

Elevation Pharmaceuticals

Jan Leschly

Before founding Care Capital, Mr. Leschly was Chief Executive of SmithKline Beecham PLC (&quot;SB&quot;) from 1994 to 2000. He joined SB as Chairman of the Worldwide Pharmaceutical business in 1990 and was elected to the Board of Directors in 1990.</br></br>Before joining SB, Mr. Leschly served as President and COO, Squibb Corporation. He joined Squibb in 1979 as Vice President, Commercial Development and in 1984 he was elected Group Vice President and a Member of the Board of Directors with responsibility for the Worldwide Pharmaceuticals Products Group. Prior to this he worked for seven years with Novo Nordisk, where he served as Executive Vice President and President of the Pharmaceutical Division.</br></br>Mr. Leschly is a member of the Boards of Directors of the American Express Company and the APM-Maersk Group.</br></br>Before his business career, Mr. Leschly made his name in professional tennis, achieving the rank of 10th in the world in 1967.</br></br>Born in Denmark, Mr. Leschly received a Master of Science in Pharmacy from the Copenhagen College of Pharmacy and a B.S. in Business Administration from the Copenhagen School of Economics and Business Administration.

Elevation Pharmaceuticals

Name

Brenton Ahrens

Heath Lukatch

Heather Preston

Jan Leschly

Firm

Work History

Brent is General Partner (West Coast) at Canaan Partners. Brent joined Canaan in 1999 and throughout his tenure has lead investments in an array of healthcare companies, with a focus on biopharma and medtech. Brent's current investment and Board seats include device developer and manufacturer Abyrx, reflux device company EndoGastric Solutions, immune-oncology drug developer Grey Wolf Therapeutics, antibiotic developer Iterum Therapeutics, device maker for chronic back pain Relievant MedSystems, life sciences tool company Unchained Labs and pain management developer Semnur. Some of his previous companies include Dexcom (DXCM), Revivant (acquired by Zolle), Peninsula Pharmaceuticals (acquired by J&J), Cerexa (acquired by FRX and Spinifex Pharmaceuticals (acquired by NVS). Prior to joining Canaan, Brent worked in both commercial and technical roles at General Surgical Innovations, Ethicon Endo-Surgery (J&J) and IAP Research. Brent earned an M.B.A. from the Tuck School of Business at Dartmouth College after graduating with a B.S. and M.S. in mechanical engineering from the University of Dayton.

Heath is Founder and Managing Partner at Red Tree Venture Capital. He has extensive experience building and advising biotech and pharma companies.

Heather Preston MD joined Pivotal in 2018 and brings 30 years of healthcare experience. Most recently she was a Firm Partner and Managing Director at TPG Biotech and she is currently a Senior Advisor to TPG. Prior to joining TPG in 2005, Dr. Preston spent two years investing with JP Morgan Partners and she was also an Entrepreneur-in-Residence with New Enterprise Associates. Prior to becoming a venture capital investor, Heather spent five years at McKinsey & Co. in New York, where she was a leader of their pharmaceutical and medical products consulting practice. She advised large pharmaceutical companies and biotechnology companies on critical strategic issues such as R&D portfolio prioritization, M&A opportunities, new technology acquisitions, new product launches and product growth strategies. Heather currently serves on the board of directors of Oxford Biomedica (LSE:OXB); Karuna Therapeutics (NASDAQ:KRTX); Entasis Therapeutics (NASDAQ:ETTX), Unchained Labs, Azura Opthalmics, Fusion Pharmaceuticals, Akouous and Avalyn Pharmaceuticals. She has previously served on multiple private and public boards including Albireo (NASDAQ:ALBO), Alder BioPharmaceuticals (NASDAQ:ALDR) (Acquired by Lundbeck in 2019), Aptalis Pharma (acquired by Forest Labs in 2014), and Elevation Pharmaceuticals (acquired by Sunovion in 2012). She was responsible for TPG Biotech’s investment in Par Pharmaceuticals (acquired by Endo Pharmaceuticals in 2015). Heather has an undergraduate degree in biochemistry from the University of London and a medical degree from the University of Oxford. She completed a post-doctoral fellowship in molecular biology at the Dana Farber Cancer Institute, Harvard University and trained in Internal Medicine at the Massachusetts General Hospital, Harvard and sub-specialized in Gastroenterology and Hepatology at UCSF. During her academic medical career, she was the recipient of a Fulbright Scholarship, a Fulbright Cancer Research Scholarship, a Harlech Scholarship and a Science and Engineering Research Council Post-doctoral Fellowship Award. Dr. Preston also serves on the Board of Trustees for the Harvard Discovery Council, the Fine Arts Museums of San Francisco, Saint Luke’s School and the Harlech Scholarship Foundation.

Before founding Care Capital, Mr. Leschly was Chief Executive of SmithKline Beecham PLC (&quot;SB&quot;) from 1994 to 2000. He joined SB as Chairman of the Worldwide Pharmaceutical business in 1990 and was elected to the Board of Directors in 1990.</br></br>Before joining SB, Mr. Leschly served as President and COO, Squibb Corporation. He joined Squibb in 1979 as Vice President, Commercial Development and in 1984 he was elected Group Vice President and a Member of the Board of Directors with responsibility for the Worldwide Pharmaceuticals Products Group. Prior to this he worked for seven years with Novo Nordisk, where he served as Executive Vice President and President of the Pharmaceutical Division.</br></br>Mr. Leschly is a member of the Boards of Directors of the American Express Company and the APM-Maersk Group.</br></br>Before his business career, Mr. Leschly made his name in professional tennis, achieving the rank of 10th in the world in 1967.</br></br>Born in Denmark, Mr. Leschly received a Master of Science in Pharmacy from the Copenhagen College of Pharmacy and a B.S. in Business Administration from the Copenhagen School of Economics and Business Administration.

Other Seats

Elevation Pharmaceuticals

Elevation Pharmaceuticals

Elevation Pharmaceuticals

Elevation Pharmaceuticals

Elevation Pharmaceuticals Management Team

4 Team Members

Elevation Pharmaceuticals has 4 executives. Elevation Pharmaceuticals's current Chief Executive Officer, President is Bill Gerhart.

Name

Work History

Title

Status

Bill Gerhart

Chief Executive Officer, President

Current

Pravin Soni

Chief Technology Officer

Current

Ahmet S Tutuncu

Senior Vice President

Current

Jaisim Shah

Senior Vice President

Former

Name

Bill Gerhart

Pravin Soni

Ahmet S Tutuncu

Jaisim Shah

Work History

Title

Chief Executive Officer, President

Chief Technology Officer

Senior Vice President

Senior Vice President

Status

Current

Current

Current

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.